Please wait a minute...
Reviews in Cardiovascular Medicine  2017, Vol. 18 Issue (1): 14-20     DOI: 10.3909/ricm0857
Review Previous articles | Next articles
The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines
Mehul A. Pragani1, Karan P. Desai2, Doralisa Morrone3, Mandeep S. Sidhu1, William E. Boden4
1 Department of Medicine, Albany Stratton Veterans Affairs Medical Center, Albany Medical Center and Albany Medical College, Albany, NY
2 Department of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD
3 Cardiovascular Medicine Division, Cardio-Thoracic & Vascular Department, University of Pisa, Pisa, Italy
4 VA New England Healthcare System, Massachusetts, Veterans Epidemiology, Research, and Informatics Center (Maveric), Boston, MA
Download:  PDF(192KB)  ( 185 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Coronary artery disease is the leading cause of mortality in the United States and can result in significant morbidity. In particular, stable ischemic heart disease (SIHD) is a condition that affects nearly 9 million individuals in the United States alone, with substantial annual health care costs related to recurrent medical visits and chronic disease management. Nitrates form a cornerstone of SIHD management by reducing myocardial oxygen consumption and increasing exercise capacity by several mechanisms, including increasing epicardial blood flow through vasodilation and decreased vascular resistance, blunting coronary steal, and reducing preload. Yet the role of nitrates may be underappreciated in clinical practice and their utilization may be limited due to concerns of tolerance to treatment, a lack of randomized data validating their ability to prevent adverse cardiovascular events, and the pervasive use of percutaneous interventions without robust attempts at implementing optimal medical therapy. In this review, we discuss both the recent ACC/AHA/ACP/AATS/PCNA/SCAI/STS and European Society of Cardiology guidelines, with a particular focus on indications, contraindications, and future directions of nitrate therapy in SIHD.
Key words:  Angina      Coronary artery disease      Stable ischemic heart disease      Nitrates     

Cite this article: 

Mehul A. Pragani, Karan P. Desai, Doralisa Morrone, Mandeep S. Sidhu, William E. Boden. The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines. Reviews in Cardiovascular Medicine, 2017, 18(1): 14-20.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0857     OR     https://rcm.imrpress.com/EN/Y2017/V18/I1/14

1. Roger VL, Go SA, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association [published corrections appear in Circulation 2011; 123:e240 and 2011; 124:e426]. Circulation. 2011;123:e18-e209.
2. O’Rourke RA. Alternative strategies for the management of chronic stable angina. Curr Probl Cardiol. 2010;35:384-446.
3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/ AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354-e471.
4. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J. 2013; 34:2949-3003.
5. Boden WE, Finn AV, Patel D, et al. Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics. Clin Cardiol. 2012;35:263-271.
6. Murrell W. Nitroglycerine as a remedy for angina pectoris. Lancet. 1879;I:80-81.
7. Kones R. Recent advances in the management of chronic stable angina II: anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag. 2010;6:749-774.
8. Gayet J, Paganelli F, Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovasc Dis. 2011;104:536-544.
9. Kimchi A, Lee G, Amsterdam E, et al. Increased exercise tolerance after nitroglycerin oral spray: a new and effective therapeutic modality in angina pectoris. Circulation. 1983;67:124-127.
10. Wittig T, Beuscher N. Increased physical performance following administration of glycerol trinitrate in spray form [article in German]. Fortschr Med. 1999;117:109113.
11. Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med. 1987;316:14401444.
12. Mu?nzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187194.
13. Jakschik B, Needleman P. Sulfhydryl reactivity of organic nitrates: biochemical basis for inhibition of glyceraldehyde-P dehydrogenase and monoamine oxidase. Biochem Biophys Res Commun. 1973;53:539544.
14. Daiber A, Oelze M, Wenzel P, et al. Nitrate tolerance as a model of vascular dysfunction: roles for mitochondrial aldehyde dehydrogenase and mitochondrial oxidative stress. Pharmacol Rep. 2009;61:33-48.
15. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99:8306-8311.
16. Knot HJ. Nitrate tolerance in hypertension: new insight into a century-old problem. Circ Res. 2003;93:799-801.
17. Gerzanich V, Ivanov A, Ivanova S, et al. Alternative splicing of cGMP-dependent protein kinase I in angiotensin-hypertension: novel mechanism for nitrate tolerance in vascular smooth muscle. Circ Res. 2003;93:805-812.
18. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989;13:786-795.
19. Graboys TB, Lown, B. Nitroglycerin: the “mini” wonder drug. Circulation. 2003;108:e78-e79.
20. Fox K, Garcia MA, Ardissino D, et al; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-1381.
21. Thadani U, Wittig T. A randomized, double-blind, placebo-controlled, crossover, dose-ranging multicenter study to determine the effect of sublingual nitroglycerin spray on exercise capacity in patients with chronic stable angina. Clin Med Insights Cardiol. 2012;6:87-95.
22. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport. 1993;4:1027-1030.
23. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25-31.
24. Basta LL, Raines D, Najjar S, Kioschos JM. Clinical, haemodynamic, and coronary angiographic correlates of angina pectoris in patients with severe aortic valve disease. Br Heart J. 1975;37:150-157.
25. Tebbe U, Neuhaus KL, Sauer G, et al. Nitrates in aortic valve disease: acute and chronic effects. Z Kardiol. 1983;72(suppl):152-155.
26. Henderson R, O’Flynn N. Management of stable angina: summary of NICE guidelines. Heart. 2012;98:500-507.
27. Steg PG, De Silva R. Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence? J Am Coll Cardiol. 2014;64:253-255.
28. Bangalore S, Steg G, Deedwania P, et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-1349.
29. Wilson J. Stable ischemic heart disease. Ann Intern Med. 2014;160:ITC1-1.
30. Parker JO, Vankoughnett KA, Farrell B. Nitroglycerin lingual spray: clinical efficacy and dose-response relation. Am J Cardiol. 1986;57:1-5.
31. Wei J, Wu T, Yang Q, et al. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol. 2011;146:4-12.
32. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232-240.
33. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
34. BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:25032515.
35. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.
36. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677-687.
37. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124.
38. Serruys PW, Ong AT, van Herwerden LA, et al. Fiveyear outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575-581.
39. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-972.
40. Dagenais GR, Lu J, Faxon DP, et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011;123:1492-1500.
41. Morrone D, Marzilli M, Kolm P, et al. Do clinical trials in ischemic heart disease meet the needs of those with ischemia? J Am Coll Cardiol. 2015;65:1596-1598.
42. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432-2446.
43. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association [published corrections appear in Circulation 2010;121:e260 and 2011;124:e425]. Circulation. 2010;121:e46-e215.
44. Mancini GB, Hartigan PM, Shaw LJ, et al. Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. JACC Cardiovasc Interv. 2014;7:195-201.
45. Panza JA, Holly TA, Asch FM, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2013;61:1860-1870.
46. Aldweib N, Negishi K, Hachamovitch R, et al. Impact of repeat myocardial revascularization on outcome in patients with silent ischemia after previous revascularization. J Am Coll Cardiol. 2013;61:1616-1623.
[1] Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[2] Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.
[3] Zhanru Qi, Hongyan Zheng, Zhonghai Wei, Qing Dai, Jun Xie, Lian Wang, Jingmei Zhang, Jie Song. Short-term and long-term outcomes of bailout versus planned coronary rotational atherectomy[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 309-314.
[4] Yuhong Liu, Zhihuan Zeng, Xing Yu, Tudi Li, Yusi Yao, Rong Chen, Jianyi Zheng. Impact of lipoprotein(a) on long-term outcomes after percutaneous coronary intervention in patients with reduced low-density lipoprotein cholesterol[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 147-153.
[5] Christian O. Koelbl, Zoran S. Nedeljkovic, Alice K. Jacobs. Coronary Chronic Total Occlusion (CTO): A Review[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 33-39.
[6] Akanksha Agrawal, Deepanshu Jain, Eyob L. Feyssa, Aman M. Amanullah. Utility of Dobutamine Stress Echocardiography in Cardiac Risk Stratification of Patients Undergoing Orthotopic Liver Transplantation[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 146-154.
[7] Raghunandan Muppidi, Laura Spranklin, William Scialla, Nauman Islam, Ronald Freudenberger, Robert Malacoff. Cardiotoxicity of Anticancer Therapies[J]. Reviews in Cardiovascular Medicine, 2015, 16(4): 225-234.
[8] Prakash Suryanarayana, Shubha Kollampare, Mohammad Reza Movahed. Anomalous Origin of the Right Coronary Artery From the Left Anterior Descending Artery With Anomalous Course Between the Great Vessels: A Case for Conservative Management With Review of the Literature[J]. Reviews in Cardiovascular Medicine, 2015, 16(3): 221-224.
[9] Prakash C. Deedwania. Management of Patients With Stable Angina and Type 2 Diabetes[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 105-113.
[10] Paolo Gresele, Emanuela Falcinelli, Stefania Momi, Daniela Francisci, Franco Baldelli. Highly Active Antiretroviral Therapy–related Mechanisms of Endothelial and Platelet Function Alterations[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 9-20.
[11] Sophie Mavrogeni, Theodoros Dimitroulas, Sherine Gabriel, Petros P. Sfikakis, Gerald M. Pohost, George D. Kitas. Why Currently Used Diagnostic Techniques for Heart Failure in Rheumatoid Arthritis Are Not Enough: The Challenge of Cardiovascular Magnetic Resonance Imaging[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 320-331.
[12] Ehtesham Ul Haq, Emile Kleyn, Bassam Omar. Painful Palpitations: Chest Pain Associated With Postextrasystolic ST Depression[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 358-361.
[13] Stuart W. Rosenbush, Jeremy M. Parker. Height and Heart Disease[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 102-108.
[14] Shrinivas Hebsur, Erik Vakil, William J. Oetgen, Princy N. Kumar, Daisy F. Lazarous. Influenza and Coronary Artery Disease: Exploring a Clinical Association With Myocardial Infarction and Analyzing the Utility of Vaccination in Prevention of Myocardial Infarction[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 168-175.
[15] Marco Gennari, Elisa Gambini, Beatrice Bassetti, Maurizio Capogrossi, Giulio Pompilio. Emerging Treatment Options for Refractory Angina Pectoris: Ranolazine, Shock Wave Treatment, and Cell-Based Therapies[J]. Reviews in Cardiovascular Medicine, 2014, 15(1): 31-37.
No Suggested Reading articles found!